Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19484531 | 0.88 | BRD4 (0.52) | BRD4CREBBPADORA2AADORA1ADORA2B | |
| SCHEMBL19484528 | 0.88 | BRD4 (0.52) | BRD4CREBBP | |
| SCHEMBL19460468 | 0.86 | ALDH1A1 (0.40) | BRD4CREBBPADORA2AADORA1 | |
| SCHEMBL19489527 | 0.83 | CREBBP (0.52) | BRD4CREBBP | |
| SCHEMBL19489833 | 0.83 | CREBBP (0.53) | BRD4CREBBP | |
| SCHEMBL19489782 | 0.82 | CREBBP (0.49) | BRD4CREBBPADORA2A | |
| SCHEMBL19489599 | 0.81 | BRD4 (0.58) | BRD4CREBBP | |
| SCHEMBL19489562 | 0.80 | BRD4 (0.65) | BRD4CREBBP | |
| SCHEMBL19460479 | 0.80 | CREBBP (0.67) | BRD4CREBBP | |
| SCHEMBL19489684 | 0.80 | BRD4 (0.44) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | claimed |
| WO-2017184462-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | claimed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | claimed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2017184462-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202360-B2 | Therapeutic compounds | EP300, BRDT, BRPF3 | BRD4 5/4885CREBBP 32/4885ADORA2A 3878/4885 |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | BRD4 5/4885CREBBP 32/4885ADORA2A 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.